Navigation Links
Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Date:1/13/2009

Presentation Scheduled for Thursday, January 15th at 1:00PM PT

NEW YORK, Jan. 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the J.P. Morgan 27th Annual Healthcare Conference being held in San Francisco.

Mr. Weiss' presentation will be webcast live on Thursday, January 15th at 1:00pm PT and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

    KERYX CONTACT:
    Lauren Fischer
    Director - Investor Relations
    Keryx Biopharmaceuticals, Inc.
    Tel: 212.531.5965
    E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
9. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
10. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
11. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... research organization (CRO) has validated a 0.2 ng/mL lower limit (LLOQ) assay for ... a 0.5 ng/mL LLOQ assay, the ultra-low trace nicotine assay meets additional needs ...
(Date:4/27/2017)... ... April 27, 2017 , ... Mitotech S.A, a Luxembourg ... Hereditary Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic disease that leads ... eye drops in a group of 20 patients carrying 11778, 14484 and 3460 mutations ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... flow controllers based on capillary thermal mass flow technology provide exponentially more accurate ... applications. Over 80% of all industrial processes—such as those involving chemical reactions, ...
(Date:4/27/2017)...  Pendant Biosciences, Inc. (formerly Nanoferix, Inc.), a privately-held ... delivery technologies, today announced that it has been accepted ... Toronto . Shawn Glinter , ... "We are excited to become part of the JLABS ... honored to be the first Tennessee ...
Breaking Biology Technology:
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
Breaking Biology News(10 mins):